RxDoctor Payments Data

Joel Brown, MD

Ophthalmology · Pittsburgh, PANPI 1376509141

Payments from drug & device makers

$12,327in general payments, 2019–2025

Across 374 payments — averaging $32.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • NEW World Medical,inc.$3K
  • AbbVie$2K
  • Bausch & Lomb Americas Inc.$1K
  • Sun Pharmaceutical Industries Inc.$722
  • Tarsus Pharmaceuticals, Inc.$635
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$12,288100%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,327 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$158,567
Medicare patients
583
Services billed
1,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$73,170
XiidraLifitegrast47$69,459
LumiganBimatoprost73$46,620
Cyclosporine61$44,378
Prednisolone Acetate240$11,590
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$5,815
MoxifloxacinMoxifloxacin Hcl169$3,110
Ketorolac Tromethamine185$3,036
Latanoprost310$2,959
Fluorometholone17$2,102
Brimonidine Tartrate34$1,092
Tobramycin-DexamethasoneTobramycin/Dexamethasone31$1,072
Timolol Maleate80$932
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$843
ErythromycinErythromycin Base36$357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$2,350$119,790133 claims
Bausch & Lomb Americas Inc.Xiidra$1,313$69,45947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →